Zobrazeno 1 - 10
of 198
pro vyhledávání: '"Recombinant human follicle stimulating hormone"'
Publikováno v:
Risk Management and Healthcare Policy, Vol Volume 17, Pp 1387-1394 (2024)
Hongchao Li,1 Wei He,2 Hongbo Lin,3 Angying Du,4 Xue Zhang,5 Han Yang,5 Shuli Qu5 1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China; 2Fertility and Reproductive Medicine C
Externí odkaz:
https://doaj.org/article/dc33a4cf7ed14adf9d05cbc51afd2e11
Autor:
Bum Chae Choi, Canquan Zhou, Hong Ye, Yun Sun, Ying Zhong, Fei Gong, Ivan Sini, Nadezda Abramova, Salvatore Longobardi, Miranda Hickey, Thomas D’Hooghe
Publikováno v:
Reproductive Biology and Endocrinology, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background Ovarian stimulation during medically assisted reproduction treatment should be individualized to optimize outcomes and reduce complications. This study assessed whether use of the recombinant human follicle-stimulating hormone (r-
Externí odkaz:
https://doaj.org/article/b79e2ca0ecf04ff5b04b143c111a9846
Autor:
Klaus F. Bühler, Robert Fischer, Patrice Verpillat, Arthur Allignol, Sandra Guedes, Emmanuelle Boutmy, Wilma Bilger, Emilia Richter, Thomas D’Hooghe
Publikováno v:
Reproductive Biology and Endocrinology, Vol 19, Iss 1, Pp 1-14 (2021)
Abstract Background This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f®) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP®), during assisted reproductive
Externí odkaz:
https://doaj.org/article/60d9a3f7bb574ae1acea1b0894849d16
Publikováno v:
Reproductive Biology and Endocrinology, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background The use of recombinant human follicle-stimulating hormone (r-hFSH) in ovarian stimulation protocols for infertility treatment in assisted reproductive technology (ART) clinical practice is well established. More recent advancement
Externí odkaz:
https://doaj.org/article/feb8cc0030084b0591e3d57ae69aaf4f
Publikováno v:
International Journal of Women's Health, Vol Volume 11, Pp 11-21 (2019)
Pierre Zitoun,1 Jaya Parikh,2 Martine Nijs,3 Wenjie Zhang,4 Rachel Levy-Toledano,5 Boxiong Tang6 1American Hospital of Paris, Neuilly-sur-Seine, France; 2Lister Fertility Clinic, London, UK; 3Nij Geertgen, Elsendorp, the Netherlands; 4WG Group, New Y
Externí odkaz:
https://doaj.org/article/7e0eaed907714e1ab5192351a2be51ce
Publikováno v:
Biomedicines, Vol 10, Iss 6, p 1312 (2022)
It is a challenge to obtain sufficient eggs during in vitro fertilization (IVF) in women with impending ovarian failure (IOF)/diminished ovarian reserve (DOR). Although studies have suggested that more than one wave of follicle growth exists, the eff
Externí odkaz:
https://doaj.org/article/c61c7fccfdfc46b3b00fbef8eae2fde5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maria Sinegubova, Ivan Vorobiev, Anatoly Klishin, Dmitry Eremin, Nadezhda Orlova, Natalya Orlova, Mikhail Polzikov
Publikováno v:
Pharmaceutics, Vol 14, Iss 1, p 96 (2022)
Recombinant human follicle stimulating hormone (r-hFSH) is widely used for infertility treatment and is subject to the development of biosimilars. There are different purification strategies that can yield r-hFSH of pharmaceutical quality from Chines
Externí odkaz:
https://doaj.org/article/c8b83b31245144bd89126b82ec3e88ff
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10769 (2021)
The uterine first-pass effect occurs when drugs are delivered vaginally. However, the effect of vaginally administered recombinant human follicle-stimulating hormone (rhFSH) on ovarian folliculogenesis and endometrial receptivity is not well establis
Externí odkaz:
https://doaj.org/article/6a5c8c1fa5134fd3a252ad9853bda48e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.